Efficacy, Toxicity, Pharmacokinetics, and in Vitro Metabolism of the Enantiomers of Ifosfamide in Mice

Cancer Research

Volumn 50, Issue 2, 1990, Pages 252-255

  Masurel, Dominique ^a   Young, Connie L ^a   Wainer, Irving W ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IFOSFAMIDE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG METABOLISM; DRUG TOXICITY; ENANTIOMER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

ANIMAL; FEMALE; HUMAN; IFOSFAMIDE; IN VITRO; MICE; MICE, INBRED CBA; MICROSOMES, LIVER; NEOPLASM TRANSPLANTATION; RHABDOMYOSARCOMA; STEREOISOMERISM; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HETEROLOGOUS;

EID: 0025017736     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wainer, I. W., and Drayer, D. E. (eds.). Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, 1988.
2. Aliens, E. J., and Testa, B. Chiral aspects of drug metabolism. Trends in Pharmacological Sciences, 7:60–64, 1986.
3. Colvin, M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin. Oncol., 9(Suppl. 1):2s-7s, 1982.
4. Brade, W. P., Herdrich, K., and Varini, M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat. Rev., 12:1–47, 1985.
5. Struck, R. F., Kirk, M. C., Mellett, L. B., El Dareer, S., and Hill, D. L. Urinary metabolites of the antitumor agent cyclophosphamide. Mol. Pharmacol., 7:519–529, 1971.
6. Kusnierczyk, H., Radzikowski, C., Paprocka, M., Budzynski, W., Rak, J., Kinas, R., Misiura, K., and Stec, W. Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates. J. Immunopharmacol., 8:455–480, 1986.
7. Misiura, K., Okruszek, A., Pankiewicz, K., Stec, W. K., Czownicki, Z., and Utracka, B. Stereospecific synthesis of chiral metabolites of ifosfamide and their determination of the urine. J. Med. Chem., 26:674–679, 1983.
8. Wainer, I. W., Stewart, C. F., Young, C. L., Masurel, D., and Frank, H. Clinical pharmacokinetics (PK) of the enantiomers of ifosfamide (IFF) in pediatric patients. Proc. Am. Soc. Clin. Oncol., 7:72, 1988.
9. Blaschke, G., and Widey, W. Metabolismus der Enantiomere des Zytostatik-ums Ifosfamid. Arzneim. Forsch, in press, 1990.
10. Blaschke, G., Hilgard, P., Maibaum, J., Niemeyer, U., and Pohl, J. Preparative Trennung der Ifosfamid-Enantiomere und ihre pharmakologisch-toxi-kologische Untersuchung. Arzneim. Forsch, 36:1493–1495, 1986.
11. Masurel, D., and Wainer, I. W. Analytical and preparative HPLC separation of the enantiomers of ifosfamide, cyclophosphamide and trofosfamide and their determination in plasma. J. Chromatogr., 490:133–143, 1989.
12. Houghton, J., Cook, R. C., Lutz, P. J., and Houghton, P. J. Melphalan:a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat. Rep., 69:91, 1985.
13. Sladek, N. E. Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res., 31:901–908, 1971.
14. Sladek, N. E., Smith, P. C., Brett, P. M., Low, J. E., Powers, J. F., Borch, R. F., and Coveney, J. R. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity. Cancer Treat. Rep., 66:1889–1900, 1982.
15. Friedman, O. M., and Boger, E. Colorimetric estimation of nitrogen mustards in aqueous media. Anal. Chem., 33:906–910, 1961.